June 12, 2013

World J Hepatol. 2013 May 27; 5(5): 237-250.

Published online 2013 May 27. doi: 10.4254/wjh.v5.i5.237.

©2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Ruben Ciria, María Pleguezuelo, Shirin Elizabeth Khorsandi, Diego Davila, Abid Suddle, Hector Vilca-Melendez, Sebastian Rufian, Manuel de la Mata, Javier Briceño, Pedro López Cillero and Nigel Heaton.

Ruben Ciria, Shirin Elizabeth Khorsandi, Diego Davila, Abid Suddle, Hector Vilca-Melendez, Nigel Heaton, Institute of Liver Studies, King’s College Hospital, London SE5 9RS, United Kingdom

María Pleguezuelo, Manuel de la Mata, Unit of Hepatology and Liver Transplantation, University Hospital Reina Sofía, s/n 1400 Córdoba, Spain

Sebastian Rufian, Javier Briceño, Pedro López Cillero, Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofía, s/n 1400 Córdoba, Spain

Author contributions: All the authors significantly contributed to conception and design, drafting the article and revising it critically and gave final approval of the version to be published.

Correspondence to: Ruben Ciria, MD, PhD, Institute of Liver Studies, King’s College Hospital, Cheyne Wing, 3rd floor, Denmark Hill, London SE5 9RS, United Kingdom. rubenciria@hotmail.com

Telephone: +44-957-010439 Fax: +44-957-010949

Received August 19, 2012; Revised November 16, 2012; Accepted December 1, 2012;


Hepatitis C virus (HCV) is a major health problem that leads to chronic hepatitis, cirrhosis and hepatocellular carcinoma, being the most frequent indication for liver transplantation in several countries. Unfortunately, HCV re-infects the liver graft almost invariably following reperfusion, with an accelerated history of recurrence, leading to 10%-30% of patients progressing to cirrhosis within 5 years of transplantation. In this sense, some groups have even advocated for not re-transplanting this patients, as lower patient and graft outcomes have been reported. However, the management of HCV recurrence is being optimized and several strategies to reduce post-transplant recurrence could improve outcomes, decrease the rate of re-transplantation and optimize the use of available grafts. Three moments may be the focus of potential actions in order to decrease the impact of viral recurrence: the pre-transplant moment, the transplant environment and the post-transplant management. In the pre-transplant setting, it is not well established if reducing the pre transplant viral load affects the risk for HCV progression after transplant. Obviously, antiviral treatment can render the patient HCV RNA negative post transplant but the long-term benefit has not yet been fully established to justify the cost and clinical risk. In the transplant moment, factors as donor age, cold ischemia time, graft steatosis and ischemia/reperfusion injury may lead to a higher and more aggressive viral recurrence. After the transplant, discussion about immunosuppression and the moment to start the treatment (prophylactic, pre-emptive or once-confirmed) together with new antiviral drugs are of interest. This review aims to help clinicians have a global overview of post-transplant HCV recurrence and strategies to reduce its impact on our patients.

Keywords: Hepatitis C virus, Recurrence, Liver, Transplantation, Outcomes


Hepatitis C virus (HCV) is a major health problem that leads to chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC)[1]. HCV-cirrhosis is the most frequent indication for liver transplantation (LTx) in Europe and America[2]. Although accepted as the standard of care for end-stage liver disease[3], the progression of liver disease is variable, leading to re-transplantation and lower survival rates. Because of these results, concerns have been expressed regarding the appropriateness of re-transplantation for HCV and the optimal timing of surgery in an era of organ shortage[4].

The diagnosis of post-transplant HCV recurrence ideally should be histological, by protocol-driven biopsies as biochemical and serological markers for HCV are inaccurate in the post LTx population[5,6]. Although non-invasive procedures such as fibroscan are able to provide similar results in detecting early and rapidly progressive fibrosis, its use is not widely extended[7]. HCV re-infects the liver graft almost invariably following reperfusion[8]. Histological patterns of acute HCV appear between 4 and 12 wk post-transplant, followed by a concomitant rise in the HCV viral load[8,9]. Serum transaminases and HCV RNA levels usually settle but spontaneous viral clearance has not been observed post LTx. A healthy HCV carrier state does not ensue, and histological features of chronic HCV can be demonstrated in 70%-90% of recipients after 1 year and in 90%-95% after 5 years[10].

The natural history of recurrent HCV is accelerated in LTx recipients, with 10%-30% progressing to cirrhosis within 5 years of transplantation. When cirrhosis is present after liver transplantation, the rate of decompensation is > 40% at 1 year and > 70% at 3 years in liver transplant recipients with established cirrhosis versus < 5% and < 10%, respectively, in immunocompetent patients[10-12]. Some patients (2%-5%) develop a severe form of cholestatic fibrosing hepatitis, with extremely high levels of serum and intrahepatic HCV RNA, and histological cholestasis, the majority of which rapidly progress to graft failure and death[10].

Strategies to reduce post-transplant HCV recurrence aim to improve outcome, to decrease the rate of re-transplantation and optimize the use of available grafts. Potential areas where recurrence can be influenced are pre-transplant antiviral treatment (AVT), modifiable peri-operative and donor variables, and post-transplant immunosuppression AVT regimens


The rationale

The aim of pre transplant AVT is to achieve a sustained virological response (SVR) or to clear HCV RNA at time of transplant. Low HCV RNA before transplant has been shown to be associated with a reduced risk of severe recurrence. The HCV RNA load has also been shown to be an independent factor for fibrosis progression and survival[13,14]. By reducing pre transplant viral load the severity of HCV recurrence has the potential to be reduced and patient survival improved. However, it is not established if reducing the pre transplant viral load affects the risk for HCV progression after transplant[15-17].

Historically, cirrhotic patients were not considered for AVT as it was felt they would not be able to tolerate therapy and be at risk of decompensation. Currently available AVT is also less effective when started in the presence of advanced fibrosis and cirrhosis. Pegylated interferon (PEG IFN) and Ribavirin are emerging as the standard therapy for HCV and appear to be tolerated by cirrhotic patients[18,19].

Predictors of antiviral therapy response and tolerance

Drawbacks to undertaking antiviral treatment in the pre transplant population are the prevalence of genotype 1, the side effects of IFN and Ribavirin preventing full dose from being achieved, and complications related to the underlying liver disease[18,20,21]. To achieve a SVR at transplant the patient generally will need to be observed for 24 wk after completion of the antiviral course. This is difficult to achieve and may represent too long a period for a patient on the waiting list. Predictors of viral clearance include non-genotype 1 and an early virological response[22-25]. The absence of a ≥ 2 log10 reduction in HCV RNA between baseline and wk 4 has a strong negative predictive value[22-24,26,27]. This absence of an early virological response can be used as a guide to stopping treatment[26]. Pre transplant higher viral load has been reported as another predictor of SVR[22,25].

To make AVT more tolerable, various dosing strategies have been used including tailoring dose to liver function, shortening the duration of therapy or using haematopoietic growth factors[22,24,25]. In decompensated cirrhotics, reported rates of neutropaenia, thrombocytopaenia, anaemia, infection or liver decompensation range from 50%-60%, 30%-50%, 30%-60%, 4%-13% and 11%-20% respectively[22-25]. Child-Turcotte-Pugh (CTP) C patients are unable to tolerate a course of treatment[23,28]. The CTP score appears to be a more reliable predictor than Model for End-stage Liver Disease (MELD) for serious side effects that lead to discontinuation of therapy, hepatic decompensation or death[28].

Evidence regarding pre-transplant antiviral therapy

Over the past decade, there have been a small number of non-controlled studies that have assessed the efficacy of IFN and Ribavirin in HCV patients on the waiting list (Table 1). Many of the reported studies were designed to focus on the safety and tolerability of AVT, rather than HCV recurrence patterns and clinical course post LTx[22-24,26-31]. A number of different antiviral regimens and treatment periods have been studied. Non-pegylated IFN and Ribavirin using a low accelerating dose regime (LADR), appears to be well tolerated with 39% clearing HCV RNA on treatment and 21% with a SVR[23]. The best results have been reported with PEG IFN and Ribavirin, with a SVR of up to 50% depending on genotype. The trials reporting more favourable SVR often had restrictive entry criteria such as patients with clinical, biochemical or haematological evidence of decompensation being excluded. A further factor adding to the variation in SVR reported was the selection of patients who were treatment naïve or previous responders[16,32].


Table 1 The pre transplant hepatitis C virus antiviral therapy studies

Overall nearly one third of patients stopped treatment due to side effects, and the remaining patients often required dose reduction to improve tolerability. The actual number of patients who were HCV RNA negative coming to transplant was small. Of the responders, up to 80% remained HCV RNA negative after transplant[22,23,26] but long-term follow up was limited. From the available data, in the selected few, AVT can render the patient HCV RNA negative post transplant but the long-term benefit has not yet been fully established to justify the cost and clinical risk.

Who to treat?

It is estimated that 93% of listed HCV patients have a MELD ≤ 18, equivalent to CTP ≤ 7 suggesting that the majority of listed patients have stable liver function and should tolerate AVT[16]. Recommendations of the International Liver Transplant Society consensus conference (ILTS) for the selection of HCV cirrhotic patients for IFN based treatment, is to consider therapy when MELD ≤ 18/CTP ≤ 7, to use selectively when MELD 18-25/CTP 8-11 and avoid when MELD > 25/CTP > 11[16], as High MELD/CTP have an unacceptable risk of complication[23,28,30].

HCV genotype may influence the severity of HCV recurrence. European centres have reported worse outcome in genotype 1b, which may be related to host immune response[33] but this has not been verified in American studies. However, genotype is the major determinant of response to treatment. Genotypes 2 and 3 should be considered for treatment, whereas the benefit of treating genotype 1 has not been fully established.

Patients who are previous non responders to IFN and Ribavirin are not suitable as the likelihood of achieving undetectable HCV RNA is very low < 10%. Prior relapsers would be suitable for treatment as their response would be predicted to be high[34]. The ideal group for waiting list AVT are patients who are previous responders, are treatment naïve or low MELD/CTP. Typically these are patients with living donors, or have compensated cirrhosis and HCC. Living Donor Liver Transplant (LDLT) recipients typically have a lower MELD than patients with decompensated cirrhosis awaiting deceased donor liver transplantation (DDLT).

Treatment regimens

Cytopenia is more common and severe with PEG IFN compared to non PEG IFN and thus, has to be balanced against higher virological response rates observed with PEG IFN. A LADR has been recommended by ILTS, as it is thought to be better tolerated in the cirrhotic patient[16,23]. Starting doses of IFN α2b 1.5 million units three times a week, PEG IFN α2b 0.5 μg/kg per week or PEG IFN 2α 90 μg per week, all with ribavirin 600 mg/d have been recommended. The dose of ribavarin should be reduced in renal impairment. Close monitoring of haematological and biochemical parameters is required, with dose adjustments being made every two weeks to allow full dose treatment to be achieved as tolerated by the patient. Patients with no virological response after 12 wk should have therapy discontinued[26]. Estimated duration of treatment is 6 mo for genotype 2 and 3, and 12 mo for genotype 1[16]. Treating for one year may not be practicable and the best group to treat is those with low MELD scores (< 18) who would be more likely to complete the treatment. LDLT recipients are a perfect group to be treated as the transplant can be timed according to HCV RNA clearance. A minimum of 12 wk, but up to 24 wk prior to LDLT is recommended[16].

Haematological growth factors

IFN is associated with cytopenia though bone marrow suppression, whereas Ribavirin can cause anaemia by a combination of haemolysis and bone marrow suppression. Patients developing anemia during HCV therapy often have inappropriately poor serum erythropoietin responses probably related to their underlying liver disease[35]. Patients with cirrhosis receiving AVT have a high incidence of haematological side effects[30]. To try and counter this Granulocyte-Colony Stimulating Factor (G-CSF) and erythropoietin (EPO) analogues have been used to avoid antiviral dose reduction with the aim of maintaining a good virological response. Severe anemia develops in about 10% of treated patients, and requires close monitoring of hemoglobin and RBV dose reduction, which may compromise sustained virologic response[36]. The impact of haematological growth factors on avoiding complications or improving virological response has not been clearly demonstrated. Aggressive use of bone marrow analogues to allow continued AVT or to avoid a dose reduction has not translated into higher treatment success rates[28,37-39].


Donor age

Several donor factors have been identified that influence HCV recurrence, impacting on both graft and patient survival. Age has been the most widely studied. Berenguer et al[40]. identified donor age higher than 60 years as a risk factor for developing cirrhosis [HR = 1.02 (1.008-1.05)] and worse graft survival [HR = 1.05 (1.03-1.07)]. Other studies have demonstrated a relationship between accelerated fibrosis and poorer outcome in grafts from older donors[41,42]. Machicao et al[41] and Wali et al[42] reported that donors aged 50 years or more, had a median fibrosis progression rate of 2.7 units/year and time to cirrhosis of 2.2 years post transplant. In contrast, Samonakis et al[43] found that absence of maintenance steroids and azathioprine but not donor age influenced severity of HCV recurrence. Lake et al[44] analyzed data from the American Scientific Registry of Transplant Recipients, looking at the effect of donor age on the outcome of 778 hepatitis B, 3463 hepatitis C and 7429 non-viral recipients. Donor age was not a risk factor for HBV recipients, but was the strongest predictor for graft loss in HCV recipients. The risk was identifiable with donors > 40 years [HR = 1.67 (1.34-2.09); P < 0.001] and > 60 years [HR = 2.21 (1.73-2.81); P < 0.001]. Donor age was also a strong predictor for graft loss in non-viral recipients, although the age range was higher (> 60 years) and the statistical strength was lower than for HCV recipients [HR = 1.89 (1.61-2.23); P < 0.001]. Donor age ( > 50 years) was also found to be a strong factor in determining the likelihood of AVT success as measured by SVR[45]. Although there are no clear data defining the donor age at risk of severe HCV recurrence, donors over 60-70 years are generally regarded as higher risk.

Donor graft steatosis

The influence of donor microvesicular steatosis on HCV recurrence is not addressed in the literature, possibly because it is regarded as a mild and reversible condition[46]. Nevertheless, a recent study has reported that microvesicular steatosis increased the risk of initial poor graft function (IPF) (OR = 1.38 per 1 SD = 9.3%; P < 0.021)[47] and work is required to establish if it influences HCV recurrence.

The adverse influence of donor macrovesicular steatosis on graft and patient outcome has been widely studied[48-50]. Two recent publications reported that macrosteatotic grafts were safe to use in HCV recipients. Botha et al[51] found that recipients receiving mildly macrosteatotic grafts (< 15% in their classification) had a good outcome, although only 3 out of 113 donors had macrosteatosis greater 30%. Burra et al[52] reached the same conclusion, although they classified mild macrosteatosis as < 30% and only 5 patients in their series had macrosteatosis > 30%. The small number of macrosteatotic grafts assigned to HCV recipients in these series makes it difficult to draw firm conclusions. In contrast, Briceño et al[53] reported that donor graft macrosteatosis (> 30%) was a risk factor for more frequent, earlier and severe HCV recurrence post LTx. Their study had 29 recipients receiving a moderately (30%-60%) and 19 recipients receiving a severely (> 60%) steatotic graft, although lack of protocolized biopsies was a limitation to this study[54], they reported a clear relationship between donor graft steatosis > 30%, earlier viral recurrence and the development of a more severe graft fibrosis.

The significance of acquired post-LTx macrosteatosis and HCV recurrence is unclear. Baiocchi et al[55] in 1998 suggested that macrosteatosis was highly specific for HCV recurrence and sensitive in detecting HCV disease recurrence, at 3 and 12 mo, but with low specificity and not genotype-related. However, Machicao et al[56] found that macrosteatosis developing after LTx did not predict severity of HCV recurrence in the first 12 mo. The development of macrosteatosis is influenced by several factors, including body mass index (BMI), immunosuppression, alcohol and diabetes. When the factors behind macrosteatosis development in the LTx population are fully elucidated its relationship to HCV recurrence may become clearer.

Type of graft

Garcia-Retortillo et al[57] reported an analysis of 117 LTx in 116 HCV recipients, of which 22 were LDLT. Type of transplant was the only independent predictor of severe recurrence (OR = 2.5; 95%CI: 1.13-5.68; P = 0.025) and the 2-year probability of severe recurrence was higher in LDLT compared to DDLT (45% vs 22%, P = 0.019). Suggested mechanisms, to explain the more aggressive HCV recurrence observed after LDLT, included shared HLA matching, the type of immunosuppression, a higher incidence of biliary complications, and the effect of liver regeneration. However, a prospective controlled trial by Shiffman et al[58] using protocol liver biopsies in 23 LDLT and 53 DDLT found no association between graft type and HCV recurrence in terms of recipient and graft survival or fibrosis progression over 3 years. Guo et al[59] reported similar results from a retrospective study of 15 LDLT and 52 DDLT, with no difference in histological HCV recurrence rates or graft survival over 2 years. Similar short-term results have also been reported by Schmeding et al[60]. with first-year fibrosis rates and graft survival being similar between DDLT and LDLT.

Split liver transplantation shares with LDLT the issue of liver regeneration as a possible risk factor for HCV recurrence, but reported studies show no difference in histological recurrence of HCV or in survival between recipients of deceased donor whole and split livers[61,62]. These studies share the limitation that donors suitable for split grafts are usually younger than 40 years and this may be an important confounding factor.

A recent study from Selzner et al[63] on 46 LDLTs and 155 DDLTs followed up with protocol biopsies showed that the mean fibrosis stage (Metavir) was significantly higher at 12 to 48 mo post LTx, and the rate of fibrosis progression tended to be faster after DDLT than LDLT (0.19 vs 0.11 stage/year, P < 0.05). In multivariate analysis, donor age was the only variable independently associated with both surrogate outcomes. Thus, donor age > 45 years carried a relative risk of 8.17 (95%CI: 2.6-25.5, P = 0.001) for reaching fibrosis stage 3 or 4 at 2 years post LTx, suggesting that donor age rather than graft type determines progression of recurrent HCV.

HCV positive donors and co-infections

The increasing organ shortage has necessitated the use of both older and HCV+ organs. There are a small number of studies examining the use of HCV+ grafts. Donor Hepatitis C status does not seem to affect graft or recipient survival and using HCV+ livers for transplantation in HCV+ recipients seems to safely expand the organ donor pool[64]. Interestingly, a recent study has analyzed the effect of HCV+ donors stratified by age. Demonstrating a negative impact of older donor age (> 50 years) on survival and fibrosis progression in patients transplanted with HCV+ organs. According to the current evidence, using HCV+ grafts from young donors (< 50 years) for HCV recipients can produce good results, but further experience is required to establish the validity of this approach[65].

The influence of co-infections on HCV recurrence has been investigated by a number of groups. Humar et al[66] studied cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6). No correlation was found between CMV or HHV-6 serum peak and HCV viral load. But on subgroup analysis HHV-6 infection was associated with the development of more severe recurrence (hepatitis and/or fibrosis score > 2). Also, fibrosis scores at last follow up were higher in patients with CMV disease or HHV-6 infection. Burak et al[67] have also identified CMV co-infection as a risk factor for graft failure and severe fibrosis on biopsy. Considering that CMV infection occurs in approximately one quarter of HCV-infected LTx recipients, CMV donor and recipient status may be an important modifiable factor to consider.

Duclos-Vallée et al[68] reported poorer survival of co-infected HIV/HCV patients (35 patients) than that of HCV mono-infected patients (44 patients). The 2 and 5 years survival rates were 73% and 51% in co-infected, and 91% and 81% in mono-infected patients, respectively. Additionally, fibrosis-free survival rates were markedly low in co-infected patients after the second year post-transplant, whereas the majority of mono-infected patients only experienced mild recurrent hepatitis. These results are similar to our series, in which 5 of 7 HCV-infected patients died after LT at 95-784 d (median 161 d), of whom 4 patients died of recurrent HCV infection and sepsis, despite antiviral therapy in 3[69]. Longer follow-up in larger series is required before a conclusive directive can be provided for HCV/HIV co-infected patients requiring LT and the advent of more effective anti-viral therapy may transform the outlook for this group.

Ischemia-reperfusion injury

Ischemia-reperfusion injury (IRI) is a result of several peri-operative factors that can define the extended criteria donor. Factors influencing the severity of IRI include donor status (cardiac or brain death), cold and warm ischemia time, donor age, preservation solution and technical factors during retrieval. Other factors influencing IRI are type of reperfusion used and graft-related quality factors such as macrosteatosis. Because of the complexity of IRI, its inclusion in multivariate analysis usually becomes a confounding factor that is difficult to study. A study from Watt et al[70] showed worse survival outcome in HCV recipients receiving grafts with preservation injury (PI). The 1- and 3-year survival rates for these 2 groups were 78% and 59% in HCV-PI(+) versus 100% and 88% in HCV-PI(-). In addition, more patients in the PI(+) group had progressed to stage 3 or 4 fibrosis, compared to the group with no PI (-) (43% vs 9%, P = 0.02). In 2008, Killackey et al[71] reported a significant correlation between peak alanine transaminase (ALT) and the severity of IRI on reperfusion biopsy among 477 HCV recipients (of which 44 were LDLT). However, there was no correlation between the severity of IRI and the incidence or timing of histologic HCV recurrence or incidence of acute cellular rejection (ACR). Briceño et al[72] also looked at the effect of marginal donor variables on outcome in HCV recipients and IRI was a prognostic factor on univariate analysis. The same group additionally reported that, when moderate to severe IRI was associated with macrovesicular steatosis > 30%, graft survival was decreased[53]. This association has not been previously reported and deserves further study.

Immunological factors

The role of human leukocyte antigen (HLA) matching between donor and recipient in post-transplant rejection and survival has been widely studied. It has been proven to increase graft survival after kidney, heart, and other organ transplants In contrast, HLA matching is not routinely performed in LTx because its importance remains unclear. A recent meta-analysis of over 16 studies found that good HLA compatibility reduces the incidence of ACR but had no influence on graft outcomes[73].

Early acute rejection and steroid bolus treatment are considered as risk factors for HCV recurrence[74]. Langrehr et al[75] published a retrospective analysis on 165 LTx in HCV recipients with complete donor/recipient HLA typing, analyzing HCV recurrence and outcome. In this study it was shown that HLA matching reduced rejection episodes, but the severity of fibrosis progression within the first year after LTx was enhanced. Interestingly, this did not result in impaired survival in the better-matched grafts. Belli et al[76] reported on the association of MHC alleles and donor/recipient mismatch with the occurrence and the severity of recurrent HCV, drawing two conclusions. Firstly, a fully mismatched donor/recipient pair at the DRB1 locus was associated with HCV recurrence and severity. And secondly, donor age, full HLA-DRB1 donor-recipient mismatch, and HLA B14, were independent risk factors for the development of severe fibrosis.

Balan et al[77] studied HLA mismatch in a cohort of 883 LTx recipients. Overall graft survival decreased according to the total mismatch score and there was a negative effect of mismatching at the A locus on patient survival. Interestingly, there was a subgroup with DR-locus mismatch with increased recurrence of autoimmune hepatitis and primary biliary cirrhosis, while mismatch in the A locus was associated with recurrence of HCV (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9). Yoshizawa et al[78] reported two cases of LDLT between identical twins. Despite the avoidance of immunosuppression, a rapid increase in serum HCV RNA and histological recurrence of HCV by 1 mo was observed. The contribution of HLA mismatch to HCV recurrence remains unclear and other immunological factors may be involved. To date, cytokine gene polymorphisms in allograft tumor-necrosis-factor β (TNF-β), Interleukin 16 (IL-16)[79], TGF-β, IL-10, and INF-γ[80] have been proposed as novel markers to predict the severity of HCV recurrence. The innate lymphocyte population of CD56+ lymphocytes, NK and NT cells provide an important first line of defense against viral infection. Rosen et al[81] showed that the number of CD56+ lymphocytes and NK cells in peripheral blood prior to LTx was significantly lower in recipients who developed severe HCV recurrence compared to those with mild histological recurrence. There was no association between NK and viral levels, suggesting that the severity of HCV recurrence is independent of viral level and high levels of CD56+ lymphocytes are protective against recurrence More work is required to confirm the genetic components that contribute to both NK cell-mediated control of HCV recurrence and to liver injury in the transplant setting[82,83].

Recent research emphasizes the important part that host genetics play in the ability to clear acute HCV infection and to achieve SVR. Polymorphism of the IL-28B gene, which encodes the endogenous antiviral cytokine IFN-λ, are associated with SVR and natural viral clearance[84]. The prevalence of the rs8099917 G allele in HCV/HIV-1 co-infected patients is strongly associated with treatment failure in HCV genotype 1-infected patients[85]. These polymorphisms may well serve, at least in the start, as a predictor of achieving SVR.

Diabetes mellitus

Diabetes and insulin resistance have been associated with progression of fibrosis[86]. Hyperinsulinemia may cause direct stimulation of hepatic stellate cell mitogenesis and synthesis of collagen[87]. The synergy between donor age and recipient diabetes as a factor for aggressive HCV recurrence was observed by Foxton et al[88] who reported that patients with diabetes receiving a liver from a donor older than 55 years was associated with an 8.38-fold risk of progression to severe fibrosis.

In 2008, Hanouneh et al[89] performed an analysis on liver biopsies to assess the impact of metabolic syndrome (MS). Overall median rate of fibrosis progression was 0.08 units per month. On univariate analysis, high HCV RNA at 4 mo post LTx, diabetes, CMV, and MS were associated with progression of fibrosis, whereas on multivariate analysis, MS was independently associated with fibrosis progression 1 year after LTx [OR = 6.3 (1.4-28.7); P = 0.017].

More recently, Veldt et al[90] evaluated the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) to identify insulin-resistant recipients at risk for rapid fibrosis progression after LTx. They found that when this index was elevated (> 2.5) there was a risk for rapid fibrosis progression and treatment with insulin had no effect on the fibrosis progression rate, suggesting that there might be a role for treatment with insulin sensitizing agents.

The association between immunosuppression with tacrolimus, HCV and post-transplant diabetes or impaired fasting glucose has been reported[91]. The choice of immunosuppressive treatment might be decided on the basis of the patient’s pretransplantation status.


Anhepatic initiated therapy

Thymoglobulin induction: Thymoglobulin is an antithymocyte polyclonal antibody that depletes the T cell pool and can be used as an induction immunosuppressant agent during the anhepatic phase. By pre-treating with thymoglobulin and minimizing immunosuppression, cellular host immunity against HCV re-infection may be improved[92]. A retrospective study on the use of thymoglobulin induction found that lower levels of Tacrolimus were achieved but HCV recurrence rates were similar between patients who had received thymoglobulin induction therapy and tacrolimus versus tacrolimus and steroids. However, HCV RNA loads were significantly lower in the thymoglobulin group[93]. More work is required to see whether this observation is clinically significant and alters the pattern of HCV post transplant recurrence.

Adoptive immunotherapy: HCV viral levels post often exceed pre LTx, as immunosuppression suppresses the host response to HCV replication. Adoptive immunotherapy has been studied in a phase 1 trial where lymphocytes extracted from liver allograft perfusate were able to mount an anti HCV response. Activated liver allograft-derived NK cells were isolated from the perfusate (IL-2 stimulated and anti-CD3 monoclonal antibody treated to deplete T cells), and injected intravenously into the transplant recipient. Early data from the pilot study reported lower HCV RNA titers at one month post-transplant, but the effect was transient[94]. Augmentation of the NK cell response, which plays a pivotal role in innate immunity, may be an alternative approach to preventing HCV recurrence and is an area of active research[95].

Post-transplant immunosuppression

Immunosuppression is considered to be a major factor in accelerated HCV recurrence and has been an area of extensive research. The immunosuppression strategy in HCV LTx recipients was evaluated in 81 LTx programs in an international survey. The most common regimen used (41%) was based on triple therapy [Tacrolimus, Mycophenolate Mofetil (MMF) and steroids]. Steroid-free protocols were used by 7.4% of transplant groups, while 11% discontinued steroids within a week, 56% within three months and 98% within the first year[96].

Steroids: High dose steroid boluses to treat rejection increase viremia and may lead to premature HCV recurrence. It has been shown that HCV recurrence is associated with the number of rejection episodes[97]. Although the data on increased HCV viral load with steroid bolus is convincing, the effect of steroid maintenance remains controversial. Moreover, a rapid reduction in steroid dosage may be harmful for HCV recurrence[98]. Interestingly, Vivarelli et al[99] reported that it is the way that steroids are administered what impacts the recurrence; in fact while rapid steroids tapering and withdrawal exert a negative effect, low-dose steroid maintenance in the first 24 postoperative months seems to reduce the severity of HCV recurrence, in particular the degree of fibrosis associated with recurrent hepatitis.

The link between steroids and viral replication has prompted many centres to practice steroid withdrawal. However there is a lack of robust data showing the efficacy of this approach. A meta-analysis of 13 trials[100] showed that steroid avoidance was associated with lower HCV recurrence (RR = 0.90, P = 0.03), although no individual trial reached statistical significance. The heterogeneity, short-term follow-up and relatively small size of many of the trials, as well as the lack of information on steroid dosage, make conclusions less robust. Larger multicenter trials are required to clarify the influence of steroid-free regimens on HCV recurrence.

Calcineurin inhibitors: The association between oversuppression and HCV progressive disease is well recognized. However, the effect of different calcineurin inhibitors (CNIs) on HCV replication and/or progression of recurrent HCV remain controversial. Cyclosporine A (CsA) has been found to inhibit HCV replication in vitro while tacrolimus does not[101]. But the effect of CsA on HCV replication in vivo, in the setting of LTx is not clear. A meta-analysis comparing tacrolimus to CsA-based immunosuppression in HCV recipients[102] assessed the clinical, virological, and histologic post-transplant outcomes. A total of 5 randomized control trials (1995-2006) which included 366 patients were analyzed. No significant differences in mortality, graft survival, biopsy proven ACR, steroid resistant ACR or fibrosing cholestatic hepatitis between the regimens was found. But the use of different immunosuppression regimens, an era-effect, and the lack of protocol liver biopsies limit this meta-analysis.

In the LIS2T trial, immunosuppression regimens based on CsA or tacrolimus were compared according to HCV status[103]. All patients received a combination of either CsA (n = 250) or tacrolimus (n = 245) with steroids and some additionally received azathioprine (AZA). The incidence of ACR was similar in patients receiving combination therapy with AZA, whether with CsA or tacrolimus, independent of the HCV status. In HCV patients, death or graft loss was higher with tacrolimus (16%) compared to CsA (6%) (P < 0.03). The HCV recurrence rate was similar for tacrolimus and CsA but time to histological diagnosis of recurrence was longer with CsA than with tacrolimus (100 ± 50 d vs 70 ± 40 d; P < 0.05).

On the basis of current data, it is not possible to conclude that CsA by itself has a significant effect on viral replication or on the course of HCV recurrence. However, choice of CNI may influence the efficacy of AVT. As co-treatment with IFN and CsA has been shown to achieve greater inhibition of HCV replication and higher SVR rates compared to IFN alone[104]. Furthermore, SVR after IFN therapy has been found to be higher with CsA compared to tacrolimus (46% vs 27%; P = 0.03)[105]. In a pilot study[106], 38 patients with HCV recurrence receiving PEG IFN α2a and Ribavirin were randomized to continue tacrolimus or to be switched to CsA. CsA led to a modest decrease in HCV RNA levels and appeared to enhance the antiviral response to IFN and Ribavirin, but there was no difference in SVR. However this study was limited by small sample size and randomization at transplant rather than at time of significant HCV recurrence. Further randomized trials are needed to establish whether the presently available CNIs affect HCV recurrence.

Post-transplant antiviral treatment

Prophylactic therapy: Treatment with neutralizing antibodies is effective in patients transplanted for HBV, but currently there is no evidence that this strategy is effective in preventing HCV recurrence. Both polyclonal and monoclonal anti-envelope antibodies can capture and neutralize HCV in vitro[107-109]. The main target for neutralizing antibodies appears to be the various epitopes in the E2 envelope glycoprotein. HCV antibody therapy starts in the anhepatic phase and then is continued for 12 to 14 wk after transplant. Three trials[110-112] comparing high dose HCV antibody vs. low dose HCV antibody were included in a Cochrane meta-analysis[113]. There was no difference in patient and graft survival, virological response or fibrosis on histology. Discontinuation of therapy occurred in up to 35% of patients with high dose antibody and 17% with low dose antibody. Considering both the lack of clinical benefit and occurrence of side effects, there is currently no evidence to recommend prophylactic HCV antibody.

Pre-emptive therapy: Antiviral therapy after transplantation but before clinical evidence of reinfection. HCV recurrence manifests in the first 6 mo post LTx. Initiation of AVT in the early post transplant period has been proposed as a potentially more effective way of preventing it. Pre-emptive therapy refers to the initiation of AVT within 2 to 8 wk after LTx when the viral load is low and histological damage is absent[114]. However, only those patients who are well after transplant and without severe complications can receive AVT. In the general population, AVT with PEG IFN for acute HCV hepatitis can achieve high SVR rates, but in transplant patients the rate is lower at 8%-39%. The high levels of immunosuppression early post LTx make AVT less effective and dose reduction or discontinuation due to adverse events is common (up to 57% of cases)[114].

Several trials have assessed the efficacy of the pre-emptive AVT. IFN, PEG IFN and Ribavirin, alone or in combination. At present, there is no standard timing of commencement of pre-emptive treatment. It has been applied very early post LTx (as soon as patients can tolerate food), to 4-6 wk after transplant. A meta-analysis which included randomized trials assessing the use of pre-emptive AVT showed no benefit in terms of survival, graft rejection, virological response or histological changes. The proportion of patients who discontinued treatment was 31% for PEG IFN, 29% for IFN and 9% for Ribavirin. Currently, there is no evidence to recommend pre-emptive AVT to prevent HCV re-infection.

Antiviral therapy after evidence of reinfection: Directed AVT after evidence of HCV recurrence represents the mainstay of management in HCV post transplant. Most LTx centers commence AVT once liver biopsy demonstrates significant histological damage and therapy with PEG IFN and Ribavirin aims to achieve SVR as this has been associated with improved survival, reduced risk of graft failure and reduced risk of developing complications.

The therapeutic efficacy and side effects of different AVT in patients with HCV re-infected grafts have been compared in a Cochrane review[115]. Eleven trials including 389 LTx were analyzed. Dose reduction or discontinuation due to adverse effects or patient choice, was required in 87.5% and 42.9% respectively. All the trials had high-risk bias and none of them reported decompensation rates or quality of life. The antiviral regimens and dosages, the interval between the LTx and the beginning of the treatment and the duration of the therapy were heterogeneous in all trials. There was no difference in the mortality, graft rejection or re-transplantation between the intervention and control arms. Nevertheless, a higher SVR (48% vs 0%) and improvement in fibrosis occurred in the treatment group of PEG IFN and ribavarin[116]. In the comparison between two doses of PEG IFN (1.5 mg/kg per week vs 0.5 mg/kg per week) plus ribavirin, higher rates of SVR were achieved in the high-dose group (63% vs 22%). Despite there being no difference in the main outcomes, SVR has been shown to reduce mortality rates in observational studies and it is worthwhile performing further studies to assess this.

Data evaluating the effect of AVT on disease progression are scarce and results are controversial. However, it has been demonstrated that AVT with PEG IFN and ribavirin achieves higher SVR rates in mild HCV recurrence than in severe HCV recurrence[116]. AVT tolerability is a major issue as only 30% of transplant patients reach target dose and duration. Dose reduction of PEG IFN and ribavirin are needed in 39% and 45% respectively, with discontinuation of treatment in 26%. Close monitoring is required and growth factors help to avoid dose reduction/discontinuation due to cytopenia.

A recent study attempted to determine the most cost effective timing for AVT (PEG IFN and ribavirin) in advanced liver disease infected with HCV genotype 1 and concluded that treatment of patients with compensated cirrhosis was the most cost effective[117]. Four different treatment strategies in a hypothetical cohort of 4000, 55 years old, treatment naïve cirrhotics with a 17 year follow-up, were analyzed in a Markov model. The authors concluded that treatment of advanced post LTx recurrence is more cost-effective than no treatment, but it gave less survival benefit at greater cost in comparison with patients treated during compensated cirrhosis.

New drugs for HCV recurrence treatment

In view of the current results of standard antiviral therapy, there is a need to improve treatment strategies. The recent knowledge of the HCV life cycle and of structural features of the HCV proteins has supported the development of many promising directly acting antiviral agents, or “specifically targeted anti-viral therapy for hepatitis C”(STAT-C) compounds. Many of these STATs are currently in phase I-III development and will significantly change treatment options for HCV infection in the near future.

Compounds targeting HCV polyprotein procession: ns3/4a protease inhibitors: These compounds provide a high anti-viral efficacy but a low genetic barrier to resistance. However, the frequency of resistance development can be reduced by the additional administration of peg-IFN and Ribavirin. Many of these compounds are under development, however telaprevir (VX-950) and boceprevir (SCH 503034) which are the most advanced HCV NS3 protease inhibitors, have already entered phase-III clinical development and are expected to be approved in 2011⁄2012[118]. Most protease inhibitors and polymerase inhibitors are HCV genotype 1 specific. The PROVE 3 trial[119] has shown that telaprevir is highly effective in the treatment of HCV genotype-1 nonresponders or relapsers. In contrast, addition of boceprevir to standard treatment only revealed a minor impact on SVR rates in non-responders, but further trials are awaited. In addition to telaprevir and boceprevir, many NS3/4A inhibitors with promising anti-viral activities are currently investigated in phase I and II trials.

Compounds targeting HCV replication: (1) HCV NS5B polymerase inhibitors. Nucleoside analogue inhibitors (NIs) [valopicitabine (NM283), R7128, R1626, PSI-7851 or DX184]. Since these compounds can mimic the natural substrates of the polymerase, they are incorporated into the growing RNA chain and tackle the active site of NS5B, then causing direct chain termination. NIs are potentially effective against different genotypes, in contrast to NS3⁄4A inhibitors. There is a relatively high genetic barrier in the development of resistances to NIs. Valopicitabine was the first NI investigated in patients with chronic hepatitis C, but its activity was low. More effective NIs are under development; (2) Non-nucleoside analogues inhibitors (NNIs). These drugs can bind to different allosteric enzyme sites, which results in conformational protein change before the elongation complex is formed. Their application results more frequently in resistance development compared to Nis; and (3) NS5A/NS4B inhibitors. NS4B displays RNA-binding properties that are crucial in HCV-RNA replication. In vitro inhibition of NS4B has been shown to compromise HCV replication significantly. NS5A protein contributes in the regulation of HCV replication[120]. No clinical data on resistance to these compounds have been reported, and thus, results studies using multiple dose and combination therapy have to be awaited.

Conclusion and keypoints

HCV recurrence is a major concern when transplanting HCV+ patients. Several strategies to try and prevent graft infection or, if already infected, to reduce recurrence severity are available.

In the pre-transplant setting, AVT aims to achieve HCV RNA negativity at time of transplant. Presently available antivirals can produce HCV RNA negativity in highly selected patients and undetectable HCV RNA or SVR at time of transplant may influence recurrent HCV.

Probably, the most important strategy in the peri-transplant, especially in an era of organ shortage, is ideal donor-to-recipient matching. Factors like donor age, donor steatosis, recipient co-infections and recipient insulin resistance increase the risk of HCV recurrence and decrease global outcome. Interestingly, the type of graft or using young HCV+ donors does not appear to increase the risk. The role of IRI and HLA mismatch needs to be explored more, although available evidence supports the minimization of both.

In the post-transplant setting, there is no evidence for the use of HCV antibody therapy and adoptive immunotherapy is still experimental. Steroid boluses and ACR are factors associated with recurrence, and steroid free immunosuppression maintenance appears to reduce recurrence. Presently available CNIs appear to have equivalent influence on HCV recurrence but CsA in combination with AVT may produce a greater inhibition of HCV replication. Directed AVT after histological evidence of HCV recurrence is the mainstay of management, with no evidence supporting pre-emptive AVT. In the future it is strictly necessary to find out whether SVR can be achieved by combination therapies of different STAT-C compounds without PEG IFN and ribavirin. Future clinical trials need to address whether a long-term suppression of HCV replication or even SVR can be achieved with such direct antiviral combination therapies. The results of LTx for HCV will hopefully continue to improve as a greater understanding of the factors influencing recurrence is achieved.


Manuscript developed under the scope of Centro de Investigación Biomédica en Red de enfermedades hepaticas y digestivas and the IMIBIC group of Investigación traslacional en Cirugía del Trasplante de örganos Sólidos.


Supported by The contribution of Ruben Ciria has been possible thanks to the support of a scholarship from the Sociedad Española de Trasplante Hepático (SETH-2009)

P- Reviewers Gruttadauria S, Nundy S, Peters MG, Vivarelli M S- Editor Huang XZ L- Editor A E- Editor Zhang DN




Post a Comment